Trial Profile
A Phase 1b, Open-Label, Multi-Center, Dose Escalation Study of the Safety, Pharmacokinetics, and Therapeutic Activity of Cergutuzumab Amunaleukin, an Immunocytokine, Which Consists of a Variant of Interleukin 2 (IL 2v), That Targets Carcinoembryonic Antigen (CEA), and Atezolizumab, an Antibody That Targets Programmed Death-Ligand 1 (PD-L1), Administered Intravenously, in Patients With Locally Advanced and/or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cergutuzumab amunaleukin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Roche
- 15 Jan 2020 Status changed from active, no longer recruiting to completed.
- 06 May 2019 Planned End Date changed from 28 May 2019 to 1 Oct 2019.
- 06 May 2019 Planned primary completion date changed from 28 May 2019 to 1 Oct 2019.